Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death Protein 1 Inhibitor”

471 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 471 results

Testing effectiveness (Phase 2)Looking for participantsNCT07332247
What this trial is testing

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

Who this might be right for
Nasopharangeal CancerRecurrent Nasopharynx Carcinoma
Sun Yat-sen University 94
Testing effectiveness (Phase 2)Active Not RecruitingNCT06056804
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07157306
What this trial is testing

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Large-scale testing (Phase 3)Looking for participantsNCT05862064
What this trial is testing

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 606
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)UnknownNCT05564897
What this trial is testing

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Zhejiang Cancer Hospital 25
Not applicableNot Yet RecruitingNCT06549855
What this trial is testing

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Who this might be right for
Endometrial CancerEndometrioid CarcinomaMismatch Repair Deficiency
Peking University People's Hospital 10
Not applicableLooking for participantsNCT06310915
What this trial is testing

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Who this might be right for
Non-small Cell Lung Cancer Stage IIIB/IV
Guangzhou Institute of Respiratory Disease 30
Testing effectiveness (Phase 2)UnknownNCT03939962
What this trial is testing

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Who this might be right for
Gastric Cancer
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT06455124
What this trial is testing

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Who this might be right for
Rectal Cancer
Fudan University 60
Not applicableActive Not RecruitingNCT07147361
What this trial is testing

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)Cervical Squamous Cell CarcinomaLung Squamous Cell Carcinoma+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 800
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05350917
What this trial is testing

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Who this might be right for
HER2-positive or Mutated Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05475613
What this trial is testing

Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation

Who this might be right for
Liver TransplantationHepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 59
Not applicableLooking for participantsNCT06158919
What this trial is testing

PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Who this might be right for
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University 58
Testing effectiveness (Phase 2)Looking for participantsNCT07277764
What this trial is testing

Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)

Who this might be right for
Nasopharyngeal Carcinoma (NPC)Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital 23
Early research (Phase 1)Looking for participantsNCT07161414
What this trial is testing

Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Who this might be right for
Advanced Solid Tumors
AstraZeneca 40
Testing effectiveness (Phase 2)Study completedNCT04681131
What this trial is testing

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
BioAtla, Inc. 85
Testing effectiveness (Phase 2)Study completedNCT03322540
What this trial is testing

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Who this might be right for
Lung Cancer
Incyte Corporation 154
Not applicableStudy completedNCT06253364
What this trial is testing

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Who this might be right for
HCCRecurrence
Chen Xiaoping 462
Testing effectiveness (Phase 2)UnknownNCT04681287
What this trial is testing

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Henan Cancer Hospital 46
Load More Results